Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in Non-infectious Severe Uveitis
NCT03847272Phase 2Terminated
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Aug 2019
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ustekinumab in uveitis, sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoints: Percentage of remission at 30 months and Percentage of patients free of relapse at Week 24. Started Aug 2019; status: terminated.
02
Drugs
ustekinumab
03
Conditions
uveitis
Beyond the preview
Go deeper on NCT03847272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03847272.